0
0
A groundbreaking gene therapy has been shown to slow the progression of Huntington’s disease (HD) by 75% over three years, a landmark achievement offering new hope to thousands affected by this devastating condition. The experimental therapy, known as AMT-130, developed by the biotechnology company uniQure, has the potential to become the first therapy that modifies the course of Huntington’s disease rather than just managing symptoms.
UniQure, based in Amsterdam, announced on September 24, 2025, results from its pivotal Phase 1/2 clinical trial involving 29 patients diagnosed with early-to-mid stage Huntington’s disease. Among 12 participants who received the higher dose of AMT-130, disease progression was slowed by an unprecedented 75% over 36 months, as measured by the widely accepted composite Unified Huntington’s Disease Rating Scale (cUHDRS).
Huntington’s disease is a rare inherited neurological disorder caused by a genetic mutation that produces a toxic protein called huntingtin. This protein gradually damages nerve cells in the brain, leading to motor dysfunction, emotional disturbances, cognitive decline, and ultimately, severe disability. Affecting about 7 per 100,000 people worldwide, often in mid-adulthood, there has been no effective way to halt disease progression until now.
Key Findings and Developments
The gene therapy AMT-130 works by using a harmless viral vector to deliver genetic instructions directly into the brain via a one-time surgical procedure. These instructions reduce the production of the harmful huntingtin protein, targeting the root cause of the disease rather than symptoms alone.
The trial measured multiple clinical outcomes. Patients receiving the high dose showed:
-
A 75% slower decline on the cUHDRS scale, encompassing motor, cognitive, and functional aspects.
-
About 60% slower worsening in Total Functional Capacity (TFC), meaning patients maintained daily living skills longer.
-
Biomarker evidence of reduced neuronal damage, demonstrated by lowered levels of neurofilament light protein (NfL) in spinal fluid, a marker of nerve cell injury that normally increases with disease progression.
Safety data indicate the therapy was generally well tolerated, with a manageable safety profile. Though the delivery requires brain surgery and carries certain risks, these were outweighed by the significant slowing of disease progression and preserved patient function.
Expert Perspectives
Dr. Walid Abi-Saab, Chief Medical Officer at uniQure, highlighted the transformative potential: “AMT-130 reinforces the promise of precision-delivered gene therapy for neurological disorders, moving beyond symptom management to altering disease trajectories”.
Professor Ed Wild of University College London, an HD expert not involved in the study, expressed optimism: “This result changes everything. Patients who were forced to retire early due to Huntington’s have regained quality of life, with some even returning to work. It marks the dawn of a new era in HD treatment”.
Context and Background
Until now, Huntington’s disease has had no treatments that slow its underlying progression. Existing therapies focus on managing symptoms such as movement disorders and psychiatric issues but do not modify disease course. The gene therapy approach takes advantage of advances in viral vector delivery and gene-silencing techniques — a frontier in treating inherited neurological diseases.
The phase 1/2 trial used an external control group from Enroll-HD, a large natural history study, to compare the treated group’s progression against expected disease trajectories. While promising, the study involved fewer than 30 participants for the higher dose group, warranting cautious interpretation ahead of larger confirmatory trials.
Public Health Implications
The successful development of AMT-130 could revolutionize care for Huntington’s disease, prolonging functional independence and quality of life for affected individuals. This therapy represents a shift toward disease-modifying genetic treatments for inherited neurodegenerative diseases, potentially inspiring new research avenues for conditions such as ALS, Parkinson’s, and Alzheimer’s diseases.
For patients and families, a one-time treatment that substantially delays decline could reduce emotional, social, and economic burdens, while encouraging early diagnosis and intervention.
Limitations and Counterarguments
Despite these promising results, several limitations deserve consideration:
-
The trial size was small, and full peer-reviewed data are yet to be published.
-
The gene therapy requires brain surgery, which may not be suitable for all patients.
-
Long-term effects beyond three years remain unknown, necessitating ongoing surveillance.
-
Comparison to an external control rather than a randomized placebo group may introduce some bias.
Regulatory approval is pending, with uniQure planning to submit data to the U.S. Food and Drug Administration (FDA) by early 2026. The earliest availability could be in late 2026 or beyond, depending on regulatory review and manufacturing scale-up.
Practical Takeaways for Readers
For individuals living with or at risk for Huntington’s disease, this breakthrough offers cautious but significant hope. While AMT-130 is not yet widely available, continued advancements in gene therapy underline the importance of genetic counseling, early diagnosis, and clinical trial participation.
Healthcare providers should stay informed about emerging therapies that may shift treatment paradigms rapidly in the coming years.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
